(IN BRIEF) Rilzabrutinib, an investigational oral BTK inhibitor, has received orphan drug designation from the FDA for treating warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), two rare conditions with no approved treatments. This designation, aimed at addressing unmet … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged BTK inhibitor, clinical trials, FDA, IgG4-RD, IgG4-related disease, immune thrombocytopenia, ITP, multi-immune modulation, orphan drug designation, phase 2a study, phase 2b study, rare diseases, regulatory review, rilzabrutinib, Sanofi, unmet medical need, wAIHA, warm autoimmune hemolytic anemia
(IN BRIEF) Boehringer Ingelheim, via its subsidiary NBE Therapeutics, has launched a cutting-edge ADC research and development facility in Basel with a CHF 27 million investment. The center is a key part of the company’s strategic efforts to advance next-generation … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged ADC, Basel, Boehringer Ingelheim, Cancer Therapies, CHF 27 million, DGNB Certificate Gold, Jean Engela, Karl Penz, Kaspar Sutter, NBE Therapeutics, oncology research, Swiss biotech, Synaffix B.V., Vienna
(IN BRIEF) IO Biotech, a Danish med-tech company, has obtained €57.5 million in venture debt financing from the European Investment Bank, with backing from the European Commission’s InvestEU programme. The financing, structured in three committed tranches of up to €37.5 … Read the full press release
Posted in Banks, Denmark, European Union, Financial, Healthcare, Investment, Luxembourg, Pharma & Biotech, Technology
Tagged Amy Sullivan, cancer vaccine, clinical development, EIB, European Commission, immunotherapeutic, InvestEU, IO Biotech, IO102-IO103, Ioannis Tsakiris, market launch, med-tech, melanoma, oncology, Pharmaceutical, regulatory approval, T-Win® platform, venture debt
(IN BRIEF) A new White Paper, developed by the Centre for Assuring Autonomy at the University of York, the MPS Foundation, and the Bradford Institute for Health Research, warns that the benefits of AI in patient care could be lost … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI decision-support tools, AI Integration, Bradford Institute for Health Research, burnout, Centre for Assuring Autonomy, clinician autonomy, Clinicians, healthcare technology, Improvement Academy, liability sink, MPS Foundation, NHS, patient care, product liability, Professor Gozie Offiah, Professor Ibrahim Habli, Professor Tom Lawton, real-world scenarios, regulatory reform, Shared CAIRE, University of York, white paper
(IN BRIEF) Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to address a significant public health issue. Designed to protect against primary and recurrent infections caused by Chlamydia … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged asymptomatic infection, chlamydia, Chlamydia trachomatis, Fast Track Designation, Griffith University, immunogenicity, infertility, Jean-François Toussaint, mRNA vaccine candidate, pelvic inflammatory disease, phase 1/2 clinical study, pregnancy complications, public health need, Queensland Government, safety, Sanofi, Translational Science Hub, University of Queensland, US Food and Drug Administration
(IN BRIEF) SymRelief® green is the latest innovation from Symrise, formulated to revolutionize sensitive skincare with a patented synergistic complex that combines biotech-derived bisabolol and organic ginger root extract. This 100% Natural Origin Content solution, compliant with ISO 16128, delivers … Read the full press release
Posted in Apparel, Fashion & Beauty, Germany, Marketing, Pharma & Biotech
Tagged biodegradable, bisabolol, clinical efficacy, COL17A1, cosmetic ingredient, ginger root extract, halal, inflammaging, ISO 16128, kosher, natural origin content, responsible beauty, Sensitive Skin, sensitive skin solutions, skincare, sustainable, SymRelief® green, Symrise, vegan
(IN BRIEF) The EQT Foundation has opened a global call for proposals under its Breakthrough Science grants program, offering grants from €25,000 to €100,000 to researchers focused on addressing critical female health challenges with deeptech solutions. The initiative seeks to … Read the full press release
Posted in Business, Healthcare, Industrial, Investment, Pharma & Biotech, Sweden
Tagged 000, accredited institutions, Autoimmune Disorders, Breakthrough Science, cardiovascular diseases, commercialization, deeptech, diagnostics, endometriosis, EQT Foundation, female health challenges, financial support, global call for proposals, grants program, gynecological conditions, low-resource settings, maternal health, mentorship, Research & Innovation, therapeutics, Women’s Health
(IN BRIEF) The DataTools4Heart (DT4H) project, funded under the European Union’s Horizon Europe Framework, has successfully concluded its initial development phase and is set to achieve major milestones in 2025. Focused on enhancing the lifestyle of cardiovascular disease patients, DT4H … Read the full press release
Posted in Artificial Intelligence (AI), European Union, France, Healthcare, Industrial, Italy, Management, News, Pharma & Biotech, Science, Technology
Tagged AI-powered analytics, Barcelona Supercomputing Center, cardiology data reuse, cardiovascular disease, clinical data, clinician engagement, Cristian Izquierdo, data synthesis, DataTools4Heart, DT4H, eight hospitals, ESC Congress, European Union, federated learning, Horizon Europe, Laura G. Antiga, multilingual natural language processing, privacy-preserving, secure toolkit, Sophia Antipolis, stable software, unified interface, University of Barcelona
(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ATRX gene, Cancer Letters, Cancer Research UK, Dr Sally George, Federica Lorenzi, high-risk, immune cell infiltration, inflammatory pathways, macrophages, MYCN gene amplification, Neuroblastoma, Neuroblastoma UK, paediatric oncology, personalised therapy, targeted treatment, The Institute of Cancer Research, TIME, tumour immune microenvironment
(IN BRIEF) The ESC Preventive Cardiology 2025 Congress will be held in Milan from 3 to 5 April 2025 and is organized by the European Association of Preventive Cardiology, part of the ESC. The event will feature over 120 sessions … Read the full press release
Posted in Business, European Union, France, Healthcare, Industrial, Law, Management, News, Pharma & Biotech, Science
Tagged 3 April 2025, 5 April 2025, artificial intelligence, breakthrough interventions, cancer therapy-induced toxicity, cardiovascular disease, data science, diagnostics, digital cardiac rehabilitation, ESC Preventive Cardiology 2025, European Association of Preventive Cardiology, European Society of Cardiology, gender differences, heart health, interactive workshops, Italian Federation of Cardiology, Italian Strategic Plan for Cardiovascular Health, Italy, live cases, Milan, Nicolle Kränkel, Obesity, Pharmacology, press accreditation, press conference, preventive cardiology, primary prevention, public health, rehabilitation, risk estimation tools, secondary prevention, sports cardiology
(IN BRIEF) Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have announced a significant global supply agreement aimed at supporting AtomVie’s radiopharmaceutical manufacturing efforts. Under this agreement, Eckert & Ziegler will provide its high-grade non-carrier added Lutetium-177 chloride (Theralugand®) … Read the full press release
Posted in Business, Germany, Healthcare, Industrial, News, Pharma & Biotech, Science, Technology
Tagged AtomVie Global Radiopharma Inc, Bruno Paquin, CDMO, contract development, Dr. Harald Hasselmann, Eckert & Ziegler SE, global partnership, global supply agreement, GMP manufacturing, INNOVATION, life-saving therapies, non-carrier added Lutetium-177 chloride, nuclear medicine, radiopharmaceutical, radiopharmaceutical manufacturing, regulatory requirements, Theralugand®
(IN BRIEF) The Fresenius healthcare group is constructing a new facility, KabiLab D20, at Daimlerstrasse 20 on its Bad Homburg campus, set to cover 5,000 m². This modern laboratory and office building will feature state-of-the-art laboratories, 90 shared workstations, meeting … Read the full press release
Posted in Business, Construction, Environment, Financial, Germany, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged 000 m², 5, Bad Homburg, clinical nutrition leader, CO₂ reduction, Daimlerstrasse 20, Diabetes, employee relocation, Fresenius healthcare group, Fresenius Kabi Business Unit Nutrition, Fresubin enteral nutrition, heat pump, innovative products, KabiLab D20, laboratory and office building, metabolic disorders, Oberursel, patient-specific parenteral nutrition, Photovoltaic Systems, Rainwater harvesting, sustainability
(IN BRIEF) GEA has introduced a major update to its NexGen Tablet Press by launching a new set of enhanced labels designed to improve clarity and usability. The updated labels feature high-contrast visuals, refreshed icons, and integrated QR codes, enabling … Read the full press release
Posted in Business, Environment, Financial, Food & Beverage, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Technology
Tagged customer feedback, efficiency, enhanced labeling, equipment update, GEA, high-contrast graphics, INNOVATION, NexGen Tablet Press, process technology, QR codes, regulatory compliance, safety, sustainability, tablet production, upgrade, user-friendly
(IN BRIEF) A collaborative study led by Bayer and Hurdle, in partnership with top academic institutions including the University of Birmingham and the University of Edinburgh, has introduced and validated InflammAge—a novel, non-invasive saliva-based biomarker that quantifies systemic chronic inflammation, … Read the full press release
Posted in Business, Education, European Union, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology, United Kingdom
Tagged aging, Bayer, Cancer, cardiovascular disease, chronic inflammation, CRP, Dr. Daniel Martin-Herranz, Generation Scotland, Hurdle, InflammAge, lifestyle factors, neurodegenerative disorders, non-invasive testing, partnership, precision medicine, Professor Janet M Lord, Professor Riccardo E. Marioni, remote health monitoring, saliva-based DNA methylation biomarker, University of Birmingham, University of Edinburgh, Veronika Óvári
(IN BRIEF) The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherapy significantly improves event-free survival in patients with resectable gastric and gastroesophageal junction cancers compared to standard chemotherapy alone. Interim findings … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adjuvant, AstraZeneca, clinical trial, Cristian Massacesi, durvalumab, early-stage, EFS, event-free survival, FLOT chemotherapy, gastric cancer, gastroesophageal junction, GEJ cancers, global, Imfinzi, immunotherapy, locally advanced, MATTERHORN, Memorial Sloan Kettering, neoadjuvant, OS, overall survival, pathologic complete response, PCR, Phase III Trial, randomized, resectable, safety profile, tumor regression, Yelena Y. Janjigian
(IN BRIEF) Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston, establishing a hub that will drive breakthroughs in Cardiovascular, Renal, and Metabolism research while also leveraging data science and AI … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI, Alan Garber, Allston, Boston, cardiovascular, data science, drug discovery, Genentech, Harvard Enterprise Research Campus, Healthcare Innovation, Manu Chakravarthy, Maura Healey, METABOLISM, Michelle Wu, Mixed-Use Campus, partnership, Public Private Partnership, Renal, research and development, Roche, Roche Genentech Innovation Center Boston, Thomas Schinecker, USD11 Billion Investment
(IN BRIEF) QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestinal infections in the U.S. This new panel targets five major bacterial pathogens and complements the previously cleared QIAstat-Dx … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged bacterial pathogens, Campylobacter, clinical needs, diagnostic solutions, diagnostic workflows, FDA clearance, Gastrointestinal Infections, healthcare flexibility, healthcare providers, Infectious Diseases Society of America, laboratories, Nadia Aelbrecht, outpatient use, partnership, QIAGEN, QIAstat-Dx Gastrointestinal Panel 2 Mini B, QIAstat-Dx Gastrointestinal Panel 2 Mini B&V, QIAstat-Dx Rise, QIAstat-Dx system, real-time PCR, Salmonella, Shigella, STEC, syndromic testing, Yersinia enterocolitica
(IN BRIEF) The European Investment Bank has committed €150 million to a pioneering financing initiative exclusively supporting women entrepreneurs in Spain’s pharmacy sector. The investment, delivered through a covered bond issued by CBNK—a bank formed by the merger of Banco … Read the full press release
Posted in Banks, Business, Economy, European Union, Financial, Government, Healthcare, Industrial, Investment, Luxembourg, Management, News, Pharma & Biotech, Science, Society, Spain, Technology
Tagged 000 loans, 600 pharmacies, Banco Caminos, Bancofar, CBNK, commercial bank advisory programme, EIB, EIB Group Forum, Enrique Serra González, equipment, European Commission, European Investment Bank, gender equality, Gender Finance Lab, inclusive economic growth, intermediated financing programme, InvestEU Advisory Hub, license acquisition, Luxembourg, Moody's Aa1 rating, Nadia Calviño, partnership, pharmacy sector, Spain, Spanish healthcare system, women entrepreneurs, working capital, €150 million investment, €450
(IN BRIEF) QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its European Patent EP 2 276 883 B2, which covers innovations in QuantiFERON-TB Gold Plus used for TB detection. … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Law, Management, Netherlands, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged bioMérieux, CDC, Düsseldorf, European Patent EP 2 276 883 B2, infectious disease diagnostics, intellectual property, latent tuberculosis, Molecular Diagnostics, patent lawsuit, public health, QIAGEN, QuantiFERON technology, QuantiFERON-TB Gold Plus, SD Biosensor, TB detection, Thierry Bernard, tuberculosis, tuberculosis control, Unified Patent Court, WHO
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?